Sir, Cost effectiveness of phacoemulsification in developing countries
I read with interest the article by Hennig et al 1 describing the outcomes of high-volume phacoemulsification in Nepal. Although patients' expectations of cataract surgery will undoubtedly increase in future, it is important to remember that more than 18 million people in developing nations are blinded by cataracts, with the number increasing each year.
Studies have shown that the percentage of patients with good visual outcomes with phacoemulsification is comparable to that of manual small-incision cataract surgery (MSICS). 2, 3 The reported cost for consumables performing phacoemulsification with a rigid intraocular lens (IOL) was US$0.50 more than MSICS. 1 However, this cost differential can become quite significant when the total volume of cases is considered. For the 8955 phacoemulsification surgeries performed in this series, an additional $4477.50 could have been saved with MSICS, which can be used for consumables for more than 1000 additional patients. In addition, the authors rightly point out that this cost does not take into account the cost of the phaco machine and its maintenance. In contrast, MSICS is considerably less dependent on expensive equipment and costs less in consumables. [2] [3] [4] It would be interesting to know the density of the cataracts, whether sutures were required to close the 5 mm phaco wound, and the resultant astigmatism. It has been shown that MSICS causes less postoperative oedema, 2,3 which may be quite significant in phacoemulsification, depending on the density of the nucleus. The majority of patients in underserved areas of developing countries usually present only when the cataracts are quite advanced. One potential advantage of phacoemulsification may be the slightly lower amount of surgically induced astigmatism 3,5 but a 5 mm wound may cause more astigmatism than with a foldable IOL. In summary, I feel that there are many factors that should be considered when using phacoemulsification in a high-volume setting in developing regions, and a prospective comparative study would go a long way to answering these questions. Nevertheless, I congratulate the authors on their results and commend them for their good work in Nepal and India.
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Dr Tan mentions that MSICS causes less post-operative corneal oedema, particularly in very dense nuclei. For this reason, all eyes likely to have hard nuclei had MSICS in this study.
Out of the 8410 phaco with 5-mm scleral tunnel incisions and rigid PMMA IOL, 24 (0.28%) required sutures to close the wound. Because this was a retrospective study, it was not possible to collect data on induced astigmatism. Although the 5-mm incision is larger, it is more posterior, and may cause no more astigmatism than the 3-mm clear corneal wound.
We are in complete agreement with Dr Tan that the best way to answer these questions is in a prospective study. We have recently obtained ethical approval for a prospective trial of rigid vs foldable IOL following phacoemulsification in Nepal, and we hope to begin recruitment later this year.
